Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-03-01
2011-03-01
Kosack, Joseph R (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S375000, C514S249000, C514S266200, C514S338000, C514S364000, C514S365000, C514S275000, C514S256000, C514S252050, C544S238000, C544S292000, C544S329000, C544S332000, C544S356000, C548S131000, C548S161000, C548S222000, C548S204000, C546S271700
Reexamination Certificate
active
07897627
ABSTRACT:
The present invention relates to compounds of formulawhereinAr, Het, R1and n are as defined herein and to pharmaceutically suitable acid addition salts, optically pure enantiomers, racemates or diastereomeric mixtures thereof. Compounds of formula I are orexin receptor antagonists and are useful in the treatment of sleep apnea, narcolepsy, insomnia, parasomnia, jet lag syndrome, circadian rhythms disorder and sleep disorders associated with neurological diseases.
REFERENCES:
patent: 2003/0176454 (2003-09-01), Yamada et al.
patent: 2006/0004013 (2006-01-01), Kimura et al.
patent: 2007/0117798 (2007-05-01), Kimura et al.
patent: 2007/0117839 (2007-05-01), Kimura et al.
patent: 2007/0219181 (2007-09-01), Kimura et al.
patent: 2008/0280948 (2008-11-01), Baumann et al.
patent: 2009/0181965 (2009-07-01), Baumann et al.
patent: 1950211 (2008-07-01), None
patent: 9404487 (1994-03-01), None
patent: 9965884 (1999-12-01), None
patent: WO 0027842 (2000-05-01), None
patent: WO 01/47897 (2001-07-01), None
patent: 0187845 (2001-11-01), None
patent: WO 03/002561 (2003-01-01), None
patent: WO 2004/069185 (2004-08-01), None
patent: 2004110350 (2004-12-01), None
patent: 2005115990 (2005-12-01), None
patent: 2006058905 (2006-06-01), None
patent: 2006112550 (2006-10-01), None
patent: 2006112551 (2006-10-01), None
patent: WO 2006/111549 (2006-10-01), None
patent: 2007058304 (2007-05-01), None
patent: 2007058305 (2007-05-01), None
patent: 2007102580 (2007-09-01), None
patent: 2007135969 (2007-11-01), None
patent: 2007135970 (2007-11-01), None
patent: 2007139149 (2007-12-01), None
patent: 2008013213 (2008-01-01), None
patent: WO 2008065626 (2008-06-01), None
Siegel, Annu Rev. Psychol. vol. 55, pp. 125-148 (2004).
Delecea et al., Proc. Natl. Acad. Sci. USA vol. 95 pp. 322-327 (1998).
Sakurai et al., Cell vol. 92, pp. 573-585 (1998).
Sakurai, Regulatory Peptides vol. 126 pp. 3-10 (2005).
Peyron et al., J. Neurosci. vol. 18, pp. 9996-10015 (1998).
Nambu et al., Brain Res. vol. 827 pp. 243-260 (1999).
Chemelli et al., Cell, vol. 98 pp. 437-451 (1999).
Lin et al., Cell. vol. 98 pp. 365-376 (1999).
Nishino et al., Lancet vol. 355 pp. 39-40 (2000).
Peyron et al., Nature Medicine vol. 6 pp. 991-997 (2000).
Mignot et al., Sleep vol. 11 pp. 1012-1020 (1997).
Piper et al., Eur. J. Neuroscience vol. 12, pp. 726-730 (2000).
Sakamoto et al., Regul. Pept. vol. 118, pp. 183-191 (2004).
Ida et al., Biochem. Biophys. Res. Comm. vol. 270, pp. 318-323 (2000).
Kuru et al., Neuroreport vol. 11 pp. 1977-1980 (2000).
Winsky Sommerer et al., J. Neuroscience vol. 24 pp. 11439-11448 (2004).
Chang et al., Neurosci. Res. vol. 56 pp. 356-362 (2006).
Suzuki et al., Brain Research vol. 1044, pp. 116-121 (2005).
Digby et al., J. Endocrinol. vol. 191 pp. 129-136 (2006).
Expert Opin. Ther. Patents vol. 16(5) pp. 631-646 (2006).
Current Opinion in Drug Discovery & Development vol. 9(5) pp. 551-559 (2006).
J. Neurosci. vol. 20(20) pp. 7760-7765 (2000).
Neurosci. Lett. vol. 341(3) pp. 256-258 (2003).
Malherbe et al., Mol. Pharmacol. vol. 64 pp. 823-832 (2003).
Weggen, et al., Nature vol. 414, pp. 212-216 (2001).
Morihara et al., J. Neurochem. vol. 83, pp. 1009-1012 (2002).
Jantzen et al., J. Neuroscience, vol. 22, pp. 226-254 (2002).
Takahashi et al., J Biol. Chem. vol. 278 pp. 18644-18670 (2003).
Beher et al., J. Biol. Chem. vol. 279 pp. 43419-43426 (2004).
Lleo et al., Nature Med. vol. 10, pp. 1065-1066 (2004).
Kukar et al., Nature Med. vol. 11 pp. 545-550 (2005).
Perretto et al., J. Med. Chem, vol. 48 pp. 5705-5720 (2005).
Clarke et al., J. Biol. Chem. vol. 281 pp. 31279-31289 (2006).
Stock et al., Bioorg. Med. Chem. Lett. vol. 16, pp. 2219-2223 (2006).
Narlawar et al., J. Med. Chem. vol. 49 pp. 7588-7591 (2006).
McPhee et al. J. Med. Chem. Soc. vol. 66 p. 1132 (1944).
Yang et al., J. Org. Chem. vol. 67(21) p. 7429 (2002).
Dorwald F. A., Side Reactions in Organic Synthesis 2005, Wiley, VCH Weinheim Preface & Chapter 1 included (pp. 1-16).
Kubinyi, 3D QSAR in Drug Design: Ligand Protein Interactions & Molecular Similarity vol. 2-3, Springer, 1998, 800 pgs. relevant pages attached (pp. 243-244).
Office Action mailed May 20, 2010 in copending U.S. Appl. No. 12/348,370.
Office Action mailed Jun. 28, 2010 in copending U.S. Appl. No. 12/114,852.
Knust Henner
Nettekoven Matthias
Pinard Emmanuel
Roche Olivier
Rogers-Evans Mark
Coughlin Matthew P
Hoffmann-La Roche Inc.
Johnston George W.
Kosack Joseph R
Prior Kimberly J.
LandOfFree
Heteroaryl derivatives as orexin receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heteroaryl derivatives as orexin receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heteroaryl derivatives as orexin receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2688018